Method for determining coagulation activation and device for carrying out said method

• US 7,767,458 B2
• Filed: 02/22/2006
• Issued: 08/03/2010
• Est. Priority Date: 02/22/2005
• Status: Active Grant

• Current Assignee: Technoclone Gesellschaft M.B.H.
• Original Assignee: Technoclone Gesellschaft M.B.H.
• Inventors: Binder, Bernd
• Primary Examiner(s): WALLENHORST, MAUREEN
• Application Number:
  US11/884,966
• Publication Number:
  US 20080194036A1
• Time in Patent Office: 1,623 Days
• Field of Search: 436/43, 436/45, 436/47, 436/63, 436/71, 436/164, 436/165, 436/166, 436/172, 436/69, 422/63, 422/64, 422/68.1, 422/73, 422/82.05, 422/82.08, 435/2, 435/13, 600/369, 73/644.1, 73/644.3
• US Class Current: 436/69
• CPC Class Codes: C12Q 1/56 involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors

Abstract

A method is disclosed of assaying circulating microparticles contained in a sample of whole blood or blood plasma from a patient to determine the patient'"'"'s ability to generate thrombin or Factor Xa as blood-clotting factors, wherein the circulating microparticles are microparticles of platelets, endothelial cells, monocytes, and smooth muscle cells, which carry on their surfaces both negatively charged phospholipids as well as tissue factor. The results of the assay may be used to determine the ability of the patient to generate thrombin or Factor Xa as blood clotting factor based upon the circulating microparticles.

Claims

1. A method of assaying a sample of whole blood or blood plasma from a patient to determine the patient'"'"'s ability to generate thrombin or Factor Xa as blood-clotting factors, wherein the whole blood or blood plasma contains circulating microparticles of platelets, endothelial cells, monocytes or smooth muscle cells, which comprises the steps of:

(a) contacting the whole blood or blood plasma sample with a complex comprising phospholipid micelles which contain tissue factor in a concentration of 0 to 1000 ρ

m to activate the circulating microparticles in the whole blood or blood plasma sample to produce thrombin or Factor Xa, and in the case where the sample is a whole blood sample, adding to the whole blood sample, a protease inhibitor to prevent protease activation in the sample;

(b) following step (a) at a given point in time determining the amount of thrombin or Factor Xa generated by the circulating microparticles, present in the whole blood or blood plasma sample;

(c) following step (b), at a later given point in time, again determining the amount of thrombin or Factor Xa generated by the circulating microparticles, present in the whole blood or blood plasma sample, according to steps (a) and (b); and

(d) comparing the difference in the amount of thrombin or Factor Xa generated by the circulating microparticles, present in the whole blood or blood plasma sample, determined according to step (b) and according to step (c), and relating that difference against a standard calibration curve for a whole blood or blood plasma sample analyzed over the same points in time according to steps (a), (b) and (c), to determine the level of thrombin or Factor Xa produced by the circulating microparticles in the whole blood or blood plasma sample, and based upon the determined level of thrombin or Factor Xa produced by the circulating microparticles in the whole blood or blood plasma sample, determining directly the quantity of the circulating microparticles in the whole blood or blood plasma sample and based upon the quantity of the circulating microparticles in the whole blood or blood plasma sample determining the ability of the patient to generate thrombin or Factor Xa as blood clotting factors.

2. The method of assaying a sample of whole blood or blood plasma defined in claim 1 wherein the circulating microparticles of platelets, endothelial cells, monocytes or smooth muscle cells, circulate in the blood and carry on their surfaces both negatively charged phospholipids and tissue factor.

3. The method of assaying a sample of whole blood or blood plasma defined in claim 1 wherein the amount of thrombin generated by the circulating microparticles in the sample of whole blood or blood plasma is determined by measuring the change in fluorescence generated by the thrombin between step (b) and step (c).

4. The method of assaying a sample of whole blood or blood plasma defined in claim 1 wherein the phospholipid micelles contain tissue factor and wherein calcium chloride is added to the sample of whole blood or blood plasma before the circulating microparticles begin to generate thrombin.

5. A method of assaying circulating microparticles contained in a sample of whole blood or blood plasma from a patient to determine the patient'"'"'s ability to generate thrombin or Factor Xa as blood-clotting factors, wherein the circulating microparticles are microparticles of platelets, endothelial cells, monocytes, or smooth muscle cells, which carry on their surfaces both negatively charged phospholipids as well as tissue factor, which comprises the steps of:

(a) contacting the whole blood or blood plasma sample with a complex comprising phospholipid micelles to activate the circulating microparticles in the whole blood or blood plasma sample to produce thrombin or Factor Xa, and in the case where the sample is a whole blood sample, adding to the whole blood sample, a protease inhibitor to prevent protease activation in the sample;

(b) following step (a) at a given point in time determining the amount of thrombin or Factor Xa generated by the circulating microparticles, present in the whole blood or blood plasma sample;

(c) following step (b), at a later given point in time, again determining the amount of thrombin or Factor Xa generated by the circulating microparticles, present in the whole blood or blood plasma sample; and

(d) comparing the difference in the amount of thrombin or Factor Xa generated by the circulating microparticles, present in the whole blood or blood plasma sample, determined according to step (b) and according to step (c), and relating that difference against a standard calibration curve for a whole blood or blood plasma sample analyzed over the same points in time according to steps (a), (b), and (c), to determine the level of thrombin or Factor Xa produced by the circulating microparticles in the whole blood or blood plasma sample, and based upon the determined level of thrombin or Factor Xa, determining directly the quantity of the circulating microparticles in the whole blood or blood plasma sample, and based upon the quantity of the circulating microparticles in the whole blood or blood plasma sample, determining the ability of the patient to generate thrombin or Factor Xa as blood clotting factors.

6. A method of assaying circulating microparticles contained in a sample of whole blood or blood plasma from a patient to determine the patient'"'"'s ability to generate thrombin or Factor Xa as blood-clotting factors, wherein the circulating microparticles are microparticles of platelets, endothelial cells, monocytes, or smooth muscle cells, which carry on their surfaces both negatively charged phospholipids as well as tissue factor, which comprises the steps of:

(a) contacting the whole blood or blood plasma sample with a complex comprising phospholipid micelles which contain tissue factor in a concentration of 1 to 1000 ρ

m, together with calcium chloride, to activate the circulating microparticles in the whole blood or blood plasma sample, to produce thrombin or Factor Xa, and in the case where the sample is a whole blood sample, adding to the whole blood sample, a protease inhibitor to prevent protease activation in the sample;

(b) following step (a) at a given point in time determining the amount of thrombin or Factor Xa generated by the circulating microparticles, present in the whole blood or blood plasma sample;

(c) following step (b), at a later given point in time, again determining the amount of thrombin or Factor Xa generated by the circulating microparticles, present in the whole blood or blood plasma sample; and

(d) comparing the difference in the amount of thrombin or Factor Xa generated by the circulating microparticles, present in the whole blood or blood plasma sample, determined according to step (b) and according to step (c), and relating that difference against a standard calibration curve for a whole blood or blood plasma sample analyzed over the same points in time according to steps (a), (b), and (c), to determine the level of thrombin or Factor Xa produced by the circulating microparticles in the whole blood or blood plasma sample, and based upon the determined level of thrombin or Factor Xa, determining directly the quantity of the circulating microparticles in the whole blood or blood plasma sample, and based upon the quantity of the circulating microparticles in the whole blood or blood plasma sample, determining the ability of the patient to generate thrombin or Factor Xa as blood clotting factors.

7. A method of assaying circulating microparticles contained in a sample of anticoagulated whole blood from a patient to determine the patient'"'"'s ability to generate thrombin as a blood-clotting factor, wherein the whole blood contains circulating microparticles of platelets, endothelial cells, monocytes, or smooth muscle cells, which carry on their surfaces both negatively charged phospholipids as well as tissue factor, which comprises the steps of:

(a) contacting the anticoagulated whole blood sample with a complex comprising phospholipid micelles, to activate the circulating microparticles in the whole blood sample to produce thrombin;

(b) adding to the anticoagulated whole blood sample, a protease inhibitor to prevent protease activation in the sample;

(c) following steps (a) and (b) at a given point in time determining the amount of thrombin generated by the circulating microparticles, present in the anticoagulated whole blood sample, by contacting the anticoagulated whole blood sample with a fluorigenic substrate cleavable by thrombin and detecting an amount of fluorescence generated by cleavage of the fluorigenic substrate by the thrombin in the anticoagulated whole blood sample;

(d) following step (c), at a later given point in time, again determining the amount of thrombin generated by the circulating microparticles, present in the whole blood sample by again contacting the anticoagulated whole blood sample with a fluorigenic substrate cleavable by thrombin and detecting an amount of fluorescence generated by cleavage of the fluorigenic substrate by the thrombin in the anticoagulated whole blood sample; and

(e) comparing the difference in the amount of thrombin generated by the circulating microparticles, present in the whole blood sample, determined according to step (c) and according to step (d), and relating that difference against a standard calibration curve for a whole blood sample analyzed over the same points in time according to steps (a), (b), (c), and (d), to determine the level of thrombin produced by the circulating microparticles in the whole blood sample, and based upon the determined level of thrombin, determining directly the quantity of the circulating microparticles in the whole blood sample, and based upon the quantity of the circulating microparticles in the whole blood sample, determining the ability of the patient to generate thrombin as a blood clotting factor.

8. A method of assaying circulating microparticles contained in a sample of anticoagulated whole blood from a patient to determine the patient'"'"'s ability to generate thrombin as a blood-clotting factor, wherein the whole blood contains circulating microparticles of platelets, endothelial cells, monocytes, or smooth muscle cells, which carry on their surfaces both negatively charged phospholipids as well as tissue factor, which comprises the steps of:

(a) contacting the anticoagulated whole blood sample with a complex comprising phospholipid micelles, which contain tissue factor in a concentration of 1 to 1000 ρ

m, together with calcium chloride, to activate the circulating microparticles in the whole blood sample to produce thrombin;

(b) adding to the anticoagulated whole blood sample, a protease inhibitor to prevent protease activation in the sample;

(c) following steps (a) and (b) at a given point in time determining the amount of thrombin generated by the circulating microparticles, present in the anticoagulated whole blood sample, by contacting the anticoagulated whole blood sample with a fluorigenic substrate cleavable by thrombin and detecting an amount of fluorescence generated by cleavage of the fluorigenic substrate by the thrombin in the anticoagulated whole blood sample;

(d) following step (c), at a later given point in time, again determining the amount of thrombin generated by the circulating microparticles, present in the whole blood sample by again contacting the anticoagulated whole blood sample with a fluorigenic substrate cleavable by thrombin and detecting an amount of fluorescence generated by cleavage of the fluorigenic substrate by the thrombin in the anticoagulated whole blood sample; and

(e) comparing the difference in the amount of thrombin generated by the circulating microparticles, present in the whole blood sample, determined according to step (c) and according to step (d), and relating that difference against a standard calibration curve for a whole blood sample analyzed over the same point in time according to steps (a), (b), (c), and (d), to determine directly the level of thrombin produced by the circulating microparticles in the whole blood sample, and based upon the determined level of thrombin, determining the quantity of the circulating microparticles in the whole blood sample, and based upon the quantity of the circulating microparticles in the whole blood sample, determining the ability of the patient to generate thrombin as a blood clotting factor.